Impact of a multidimensional intervention in elderly patients with community-acquired pneumonia: IMIEPCAP clinical trial

Olga Herminia Torres, Eva Gil, Maria Teresa Comas, Maria Encarnación Saez, Sandra Clotet, Hector David Ramirez, Miriam Mateo, Domingo Ruiz

Research output: Contribution to journalArticleResearchpeer-review

Abstract

© 2015 SEGG. Introduction: The main objective of this study is to determine whether a multidimensional intervention applied to elderly patients admitted to hospital due to pneumonia reduces re-admissions and emergency department visits in the year after the intervention. Methodology: This is a single-centre non-pharmacological randomised clinical trial with a parallel design. Three hundred and fourteen patients will be included (157 in each arm). Eligible patients will be ≥. 65. years old and with a Barthel index ≥. 60 that are admitted to hospital due to pneumonia. Participants will be randomised to multidimensional intervention or to control group. Two months after hospital discharge the intervention group will receive a geriatric intervention, carried out by a nurse and a physician. It will include assessment of co-morbidities, nutritional, functional and cognitive status, and immunisation. The control group will receive conventional follow-up. The number of re-admissions, visits to the emergency department, functional status, survival, and institutionalisation will be evaluated one year after intervention.If the intervention shows an improvement in the studied outcomes, it would allow us to improve individual outcomes, and indirectly reduce healthcare costs using a relatively simple, standardised tool.
Original languageEnglish
Pages (from-to)37-43
JournalRevista Espanola de Geriatria y Gerontologia
Volume51
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

Keywords

  • Clinical trial
  • Comprehensive geriatric assessment
  • Elderly
  • Pneumonia
  • Secondary prevention

Fingerprint Dive into the research topics of 'Impact of a multidimensional intervention in elderly patients with community-acquired pneumonia: IMIEPCAP clinical trial'. Together they form a unique fingerprint.

Cite this